[go: up one dir, main page]

CR20170079A - Agentes de unión a cd123 y usos de estos - Google Patents

Agentes de unión a cd123 y usos de estos

Info

Publication number
CR20170079A
CR20170079A CR20170079A CR20170079A CR20170079A CR 20170079 A CR20170079 A CR 20170079A CR 20170079 A CR20170079 A CR 20170079A CR 20170079 A CR20170079 A CR 20170079A CR 20170079 A CR20170079 A CR 20170079A
Authority
CR
Costa Rica
Prior art keywords
antibodies
antigen binding
binding fragments
union
agents
Prior art date
Application number
CR20170079A
Other languages
English (en)
Inventor
Ricardo Attar
Benjamin C Harman
Francois Gaudet
Jinquan Luo
Yingzhe Li
Susan H Tam
Alexey Teplyakov
Jhon Wheeler
Sheng-Jiun Wu
Jennifer F Nemeth
Ronan Mcdaid
Steven C Pomerantz
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of CR20170079A publication Critical patent/CR20170079A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Steroid Compounds (AREA)

Abstract

En la presente invención se proporcionan anticuerpos que se unen de manera inmunoespecífica a CD123. Además, se describen polinucleótidos relacionados capaces de codificar los anticuerpos específicos de CD123 o los fragmentos de unión al antígeno proporcionados, células que expresan los anticuerpos o los fragmentos de unión al antígeno proporcionados, así como los vectores asociados y los fragmentos de unión al antígeno o los anticuerpos detectablemente marcados.
CR20170079A 2014-09-05 2015-09-03 Agentes de unión a cd123 y usos de estos CR20170079A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462046682P 2014-09-05 2014-09-05
PCT/US2015/048316 WO2016036937A1 (en) 2014-09-05 2015-09-03 Cd123 binding agents and uses thereof

Publications (1)

Publication Number Publication Date
CR20170079A true CR20170079A (es) 2017-04-27

Family

ID=54150667

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20170079A CR20170079A (es) 2014-09-05 2015-09-03 Agentes de unión a cd123 y usos de estos

Country Status (39)

Country Link
US (1) US9850310B2 (es)
EP (2) EP3722315A1 (es)
JP (2) JP6805130B2 (es)
KR (1) KR102540192B1 (es)
CN (1) CN107074956B (es)
AR (1) AR101765A1 (es)
AU (1) AU2015311931B2 (es)
CA (1) CA2959171C (es)
CL (1) CL2017000515A1 (es)
CO (1) CO2017002196A2 (es)
CR (1) CR20170079A (es)
CY (1) CY1122858T1 (es)
DK (1) DK3189081T3 (es)
EA (1) EA037647B1 (es)
EC (1) ECSP17020812A (es)
ES (1) ES2791249T3 (es)
HR (1) HRP20200745T1 (es)
HU (1) HUE048791T2 (es)
IL (1) IL250770B (es)
JO (1) JO3568B1 (es)
LT (1) LT3189081T (es)
MA (2) MA40609B1 (es)
ME (1) ME03724B (es)
MX (1) MX2017002891A (es)
MY (1) MY186337A (es)
NI (1) NI201700025A (es)
PE (1) PE20171556A1 (es)
PH (1) PH12017500472A1 (es)
PL (1) PL3189081T3 (es)
PT (1) PT3189081T (es)
RS (1) RS60305B1 (es)
SG (1) SG11201701599UA (es)
SI (1) SI3189081T1 (es)
SM (1) SMT202000253T1 (es)
TW (1) TWI693233B (es)
UA (1) UA120060C2 (es)
UY (1) UY36289A (es)
WO (1) WO2016036937A1 (es)
ZA (1) ZA201702369B (es)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS65965B1 (sr) * 2010-04-20 2024-10-31 Genmab As Proteini koji sadrže fc heterodimernih antitela i postupci njihove proizvodnje
WO2016116626A1 (en) 2015-01-23 2016-07-28 Sanofi Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123
US10100118B2 (en) 2015-04-08 2018-10-16 Sorrento Therapeutics, Inc. Antibody therapeutics that bind CD123
JP6688551B2 (ja) 2015-05-21 2020-04-28 ハープーン セラピューティクス，インク． 三重特異性結合タンパク質と使用方法
PL3313884T3 (pl) * 2015-06-29 2021-05-31 Immunogen, Inc. Przeciwciała anty-cd123 oraz ich koniugaty i pochodne
KR20180038560A (ko) 2015-08-28 2018-04-16 아뮤닉스 오퍼레이팅 인코포레이티드 키메라 폴리펩티드 조립체와 이의 제조 및 사용 방법
EA201891178A1 (ru) 2015-12-14 2019-01-31 Макродженикс, Инк. Биспецифичные молекулы, обладающие иммунореактивностью в отношении pd-1 и ctla-4, и способы их применения
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
MX2018014227A (es) 2016-05-20 2019-08-22 Harpoon Therapeutics Inc Proteinas de union de cadena unica de fragmento variable cd3.
CN119060177A (zh) 2016-05-20 2024-12-03 哈普恩治疗公司 单结构域血清白蛋白结合蛋白质
JP6921943B2 (ja) 2016-06-06 2021-08-18 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 増加した眼球保持を伴う眼科用融合タンパク質
EP3463464A4 (en) 2016-06-07 2020-07-01 MacroGenics, Inc. COMBINATION THERAPY
TWI790206B (zh) * 2016-07-18 2023-01-21 法商賽諾菲公司 特異性結合至ｃｄ３和ｃｄ１２３的雙特異性抗體樣結合蛋白
TWI781108B (zh) * 2016-07-20 2022-10-21 比利時商健生藥品公司 抗ｇｐｒｃ５ｄ抗體、結合ｇｐｒｃ５ｄ與ｃｄ３之雙特異性抗原結合分子及其用途
CN107840889A (zh) * 2016-09-19 2018-03-27 上海吉倍生物技术有限公司 高亲和力的抗cd123抗体及其应用
EP3515491A4 (en) * 2016-09-21 2020-09-16 Aptevo Research and Development LLC CD123 BINDING PROTEINS AND RELATED COMPOSITIONS AND PROCEDURES
AU2017363300A1 (en) 2016-11-23 2019-06-20 Harpoon Therapeutics, Inc. Prostate specific membrane antigen binding protein
BR112019010602A2 (pt) 2016-11-23 2019-12-17 Harpoon Therapeutics Inc proteínas trispecíficas para psma e métodos de uso
WO2018145075A1 (en) * 2017-02-06 2018-08-09 Dana-Farber Cancer Institute, Inc. Compositions and methods for augmenting antibody mediated receptor signaling
IL268836B2 (en) 2017-02-24 2024-04-01 Macrogenics Inc Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof
US11535668B2 (en) 2017-02-28 2022-12-27 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
WO2018166461A1 (en) * 2017-03-14 2018-09-20 Sunshine Lake Pharma Co., Ltd. Dual-target fusion proteins comprising the fc portion of an immunoglobulin
WO2018209298A1 (en) 2017-05-12 2018-11-15 Harpoon Therapeutics, Inc. Mesothelin binding proteins
CA3063362A1 (en) 2017-05-12 2018-11-15 Harpoon Therapeutics, Inc. Msln targeting trispecific proteins and methods of use
WO2019034580A1 (en) 2017-08-14 2019-02-21 Morphosys Ag HUMANIZED ANTIBODIES FOR CD3
US20210061911A1 (en) * 2017-09-07 2021-03-04 Macrogenics, Inc. Dosing Regiments of Bi-Specific CD123 x CD3 Diabodies in the Treatment of Hematologic Malignancies
EP4435007A3 (en) 2017-10-13 2024-12-25 Harpoon Therapeutics, Inc. Trispecific proteins and methods of use
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
BR112020008127A2 (pt) * 2017-10-27 2020-10-13 Pfizer Inc. anticorpos e conjugados de anticorpo-fármaco específicos para cd123 e seus usos
JP2021505637A (ja) 2017-12-12 2021-02-18 マクロジェニクス，インコーポレーテッド 二重特異性ｃｄ１６結合分子、及び疾患の治療におけるその使用
KR20200121834A (ko) 2018-02-15 2020-10-26 마크로제닉스, 인크. 변이체 cd3-결합 도메인 및 질환 치료를 위한 병용 요법에서의 그것의 용도
AU2019235523A1 (en) * 2018-03-14 2020-10-29 Novimmune Sa Anti-CD3 epsilon antibodies and methods of use thereof
JP7395508B2 (ja) 2018-05-16 2023-12-11 ヤンセン バイオテツク，インコーポレーテツド 癌を治療する方法及びｔ細胞リダイレクト治療薬の有効性を向上させる方法
MA52772A (fr) 2018-05-24 2021-04-14 Janssen Biotech Inc Anticorps anti-tmeff2 monospécifiques et multispécifiques et leurs utilisations
CR20200563A (es) 2018-05-24 2021-05-11 Janssen Biotech Inc Agentes aglutinantes de psma y usos de estos
JOP20190116A1 (ar) * 2018-05-24 2019-11-24 Janssen Biotech Inc الأجسام المضادة لتكتل التمايز 33 (cd33)، والأجسام المضادة ثنائية النوعية لتكتل التمايز 33 (cd33)/تكتل التمايز 3 (cd3) واستخداماتها
WO2020061482A1 (en) 2018-09-21 2020-03-26 Harpoon Therapeutics, Inc. Egfr binding proteins and methods of use
CN113286817B (zh) 2018-09-25 2025-01-28 哈普恩治疗公司 Dll3结合蛋白及使用方法
WO2020080853A1 (ko) * 2018-10-17 2020-04-23 주식회사 굳티셀 Lrig-1 단백질에 특이적인 결합 분자 및 이의 용도
KR20210138033A (ko) * 2019-03-11 2021-11-18 얀센 바이오테크 인코포레이티드 항-Vβ17/항-CD123 이중특이성 항체
WO2020212947A1 (en) 2019-04-19 2020-10-22 Janssen Biotech, Inc. Methods of treating prostate cancer with an anti- psma/cd3 antibody
WO2020236792A1 (en) 2019-05-21 2020-11-26 Novartis Ag Cd19 binding molecules and uses thereof
CN113912696B (zh) * 2019-07-24 2023-05-30 暨南大学 靶向cd133的结合蛋白与其应用
GB201912681D0 (en) 2019-09-04 2019-10-16 Eth Zuerich Bispecific binding agent that binds to cd117/c-kit and cd3
JP2023527609A (ja) 2020-02-21 2023-06-30 ハープーン セラピューティクス，インク． Ｆｌｔ３結合タンパク質および使用方法
AU2021235564A1 (en) 2020-03-13 2022-11-03 Janssen Biotech, Inc. Materials and methods for binding Siglec-3/CD33
CN115666727A (zh) * 2020-05-19 2023-01-31 詹森生物科技公司 包含t细胞重定向治疗剂和vla-4粘附途径抑制剂的组合物
US12024559B2 (en) * 2020-10-23 2024-07-02 Asher Biotherapeutics, Inc. Fusions with CD8 antigen binding molecules for modulating immune cell function
US11692039B2 (en) 2020-12-31 2023-07-04 Innate Pharma Multifunctional natural killer (NK) cell engagers binding to NKp46 and CD123
US20220233690A1 (en) 2021-01-28 2022-07-28 Regeneron Pharmaceuticals, Inc. Compositions and methods for treating cytokine release syndrome
AU2022278013A1 (en) * 2021-05-18 2024-01-18 Janssen Biotech, Inc. Compositions comprising a t cell redirection therapeutic and an anti-cd44 therapeutic
JP2024522069A (ja) 2021-05-19 2024-06-11 アシャ バイオセラピューティクス，インク． Ｉｌ－２１ポリペプチド及び標的化コンストラクト
CN118103070A (zh) * 2021-08-09 2024-05-28 默克专利有限公司 解偶联t细胞介导的肿瘤细胞毒性与促炎细胞因子释放的蛋白质
WO2023138666A1 (en) * 2022-01-19 2023-07-27 Utc Therapeutics (Shanghai) Co., Ltd. Circular rna and use thereof
US20230357446A1 (en) 2022-04-11 2023-11-09 Regeneron Pharmaceuticals, Inc. Compositions and methods for universal tumor cell killing
IL317227A (en) 2022-05-27 2025-01-01 Sanofi Sa Combined natural killer (NK) cells bind to NKP46 and BCMA variants with FC engineering
US20240277844A1 (en) 2023-02-17 2024-08-22 Regeneron Pharmaceuticals, Inc. Induced nk cells responsive to cd3/taa bispecific antibodies

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US6177078B1 (en) 1995-12-29 2001-01-23 Medvet Science Pty Limited Monoclonal antibody antagonists to IL-3
PT1538206E (pt) 1997-09-16 2010-04-12 Centocor Ortho Biotech Inc Método para a síntese química e construção completa de genes e genomas
US6670127B2 (en) 1997-09-16 2003-12-30 Egea Biosciences, Inc. Method for assembly of a polynucleotide encoding a target polypeptide
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
AU2005282700A1 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
JP5620626B2 (ja) 2005-03-31 2014-11-05 中外製薬株式会社 会合制御によるポリペプチド製造方法
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
AU2006317242A1 (en) 2005-11-28 2007-05-31 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
US20090182127A1 (en) 2006-06-22 2009-07-16 Novo Nordisk A/S Production of Bispecific Antibodies
AU2008343589A1 (en) 2007-12-19 2009-07-09 Centocor Ortho Biotech Inc. Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods
WO2010126066A1 (ja) 2009-04-27 2010-11-04 協和発酵キリン株式会社 血液腫瘍治療を目的とした抗IL-3Rα抗体
US9067986B2 (en) 2009-04-27 2015-06-30 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
CN102597775A (zh) * 2009-09-25 2012-07-18 佐马技术有限公司 筛选方法
RS65965B1 (sr) 2010-04-20 2024-10-31 Genmab As Proteini koji sadrže fc heterodimernih antitela i postupci njihove proizvodnje
NZ604510A (en) 2010-08-17 2013-10-25 Csl Ltd Dilutable biocidal compositions and methods of use
KR101973930B1 (ko) 2010-11-05 2019-04-29 자임워크스 인코포레이티드 Fc 도메인 내의 돌연변이를 갖는 안정한 이종이량체 항체 디자인
RS62689B1 (sr) 2011-11-04 2021-12-31 Zymeworks Inc Dizajn stabilnog heterodimernog antitela sa mutacijama u fc domenu
PT2850106T (pt) * 2012-05-18 2022-07-18 Aptevo Res & Development Llc Imunofusão biespecífica (bif) de scfv de ligação a cd123 e cd3

Also Published As

Publication number Publication date
MA53145A (fr) 2021-05-19
ES2791249T3 (es) 2020-11-03
EA201790530A1 (ru) 2018-03-30
TWI693233B (zh) 2020-05-11
PT3189081T (pt) 2020-05-25
DK3189081T3 (da) 2020-05-04
AU2015311931A1 (en) 2017-03-16
WO2016036937A1 (en) 2016-03-10
ECSP17020812A (es) 2018-07-31
IL250770A0 (en) 2017-04-30
NI201700025A (es) 2017-06-22
TW201625687A (zh) 2016-07-16
ME03724B (me) 2021-01-20
PL3189081T3 (pl) 2020-10-05
JP2017529838A (ja) 2017-10-12
CN107074956B (zh) 2021-11-26
SG11201701599UA (en) 2017-03-30
SI3189081T1 (sl) 2020-07-31
JP6805130B2 (ja) 2020-12-23
AR101765A1 (es) 2017-01-11
BR112017004322A2 (pt) 2017-12-05
RS60305B1 (sr) 2020-07-31
CN107074956A (zh) 2017-08-18
JP2021050216A (ja) 2021-04-01
US9850310B2 (en) 2017-12-26
CO2017002196A2 (es) 2017-07-28
EP3189081B1 (en) 2020-02-19
MX2017002891A (es) 2017-10-11
CY1122858T1 (el) 2021-05-05
ZA201702369B (en) 2018-12-19
SMT202000253T1 (it) 2020-07-08
IL250770B (en) 2020-10-29
KR20170049554A (ko) 2017-05-10
PE20171556A1 (es) 2017-10-27
MY186337A (en) 2021-07-13
HRP20200745T1 (hr) 2020-08-07
PH12017500472A1 (en) 2017-07-31
CA2959171C (en) 2023-11-14
UY36289A (es) 2016-04-01
KR102540192B1 (ko) 2023-06-02
MA40609B1 (fr) 2020-05-29
EA037647B1 (ru) 2021-04-27
JO3568B1 (ar) 2020-07-05
EP3722315A1 (en) 2020-10-14
AU2015311931B2 (en) 2020-09-03
EP3189081A1 (en) 2017-07-12
LT3189081T (lt) 2020-05-11
CA2959171A1 (en) 2016-03-10
CL2017000515A1 (es) 2018-03-16
US20160068605A1 (en) 2016-03-10
HUE048791T2 (hu) 2020-09-28
UA120060C2 (uk) 2019-09-25

Similar Documents

Publication Publication Date Title
CR20170079A (es) Agentes de unión a cd123 y usos de estos
CO2018011364A2 (es) Anticuerpos anti-il-33, composiciones, métodos y usos de los mismos
UY36974A (es) Anticuerpos anti-il1rap, moléculas de unión a antígenos biespecíficas que se unen a il1rap y cd3, y usos de estas
UY37340A (es) Antianticuerpos gprc5d, moléculas de unión al antígeno biespecíficas que se unen a gprc5d y cd3, y usos de estas
ECSP17083779A (es) Agentes de unión a inmunorreceptor de células t con dominios ig y motivo de inhibición basado en tirosina de inmunorreceptor (tigit) y usos de los mismos
ECSP18041833A (es) Anticuerpos que se unen específicamente a pd-1 y sus usos
CL2017001154A1 (es) Moléculas de unión específicas para cd73 y usos de las mismas
CO2018000882A2 (es) Constructos de anticuerpo para flt3 y cd3
UY36859A (es) Anticuerpos anti-bcma, moléculas de unión a antígenos biespecíficas que se unen a bcma y cd3, y usos de estas
CO2018000976A2 (es) Constructos de anticuerpo para cd70 y cd3
CO2018000887A2 (es) Constructos de anticuerpo biespecificos que se unen a egfrviii y cd3
EA202091540A1 (ru) Антитела к lilrb2
EA201791485A1 (ru) Анти-cd47-антитела и их применения
CO2017000506A2 (es) Receptor quimérico de antígeno cll-1
MX2017002205A (es) Receptor quimerico de antigeno (car) anti-cd123 para uso en el tratamiento de cancer.
BR112016022841A2 (pt) cadeia j modificada
UY35483A (es) Anticuerpos pac1 humanos
MX2017001008A (es) Tratamiento de cancer utilizando un receptor quimerico de antigeno cd33.
MX2016009555A (es) Proteinas de union y metodos para utilizarlas.
EA202092435A2 (ru) Моноклональные антитела против bcma
MX2017001011A (es) Tratamiento de cancer de usando un receptor quimerico de antigeno anti-bcma.
BR112017013176A2 (pt) receptores de antígenos quiméricos e métodos para usá-los
EA201791139A1 (ru) Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены
EA201791164A1 (ru) Гетеродимерные антитела, связывающие cd3 и cd38
MX380514B (es) Moléculas biespecíficas de unión a antígeno activadoras de celulas t.